Aly Karsan

Contact Information
British Columbia Cancer Research Centre
Rm 9-111, 675 West 10th Ave, Vancouver, British Columbia, Canada V5Z1L3
Tel 1-604-675-8033
Fax 1-604-675-8049
Lab Website:

Current Positions

  • Medical Director, Cancer Genetics Laboratory, Pathology and Laboratory Medicine, BC Cancer Agency
  • Head, Clinical Diagnostic Genomics, Genome Sciences Centre, BC Cancer Agency
  • Professor, Pathology and Laboratory Medicine, UBC

Research Interests

  • Myelodysplastic syndromes
  • Innate immune signaling in vascular and hematopoietic function
  • Role of Notch in cardiovascular development and angiogenesis

My lab focuses on two major areas:
(1) Understanding the molecular basis of the preleukemic bone marrow failure conditions called myelodysplastic syndromes (MDS); and
(2) Determining the role of the endothelium in the development of the hematopoietic system. With respect to both areas we have been studying the role of two pathways: innate immune signaling as represented by the Toll-like receptor (TLR) pathways, and the Notch signaling pathway.

We have recently demonstrated that microRNAs that reside on the long arm of chromosome 5 act to regulate innate immune signaling. Deletion of chromosome arm 5q is the commonest structural anomaly seen in MDS, and our current work is centred around establishing the function of these microRNAs and deregulated innate immune signaling in the manifestations of MDS. We are using a variety of in vivo transplantation assays, in vitro cell biology and cell signaling studies as well as genomic approaches to answer these questions.

In other work related to innate immune signaling, we have identified a novel protein by differential proteomic analysis that appears to act as a scaffold protein in a MyD88-independent TLR signal transduction pathway. Expression analyses indicate that this molecule is highly expressed in the microvasculature. Molecular and cellular studies to elucidate the mechanisms of action of this protein are ongoing. As well we have generated a gene-targeted mouse model that demonstrates that loss of this protein is incompatible with life past mid-gestation. Currently, we are generating a conditional gene-targeted mouse model to gain a better understanding of the physiologic role of this protein.

My lab has also had a long-standing interest in the role of Notch signaling in the endothelium. We have generated a conditional, inducible mouse model in which we are able to regulate Notch signaling. Using this and other models we are studying how endothelial cells contribute to hematopoietic development both at the initial stages of intraembryonic hematopoiesis where hematopoietic stem cells are thought to derive from the endothelium, as well as during fetal liver and adult hematopoiesis, where the endothelium may act as a niche to regulate stem cell self renewal and/or differentiation.

Selected Papers

  1. Lam J, Van Den Bosch M, Wegrzyn-Woltosz J, Parker J, Ibrahim R, Slowski K, Chang L,Martinez-Hoyer S, Umlandt P, Fuller M, Karsan A. Loss of miR-143 and miR-145 inhibithematopoietic stem cell activity but enhance progenitor activity through activation of TGFβ signaling. Nature Communications volume 9, Article number: 2418 (2018).
  2. Agrahari R, Foroushani A, Docking TR, Chang L, Duns G, Hudoba M, Karsan A*, Zare H*. Applications of Bayesian network models in predicting types of hematological malignancies. *co-senior authors Scientific Reports. Sci Rep. 2018 May 3;8(1):6951. doi: 10.1038/s41598-018-24758-5. PMID: 29725024


  1. Stockley T, Souza C, Cheema P, Melosky B,  Kamel-Reid S, Tsao M,  Spatz A, Karsan A. Evidence-Based Best Practices for EGFR-T790M Testing in Lung Cancer in Canada.. Curr Oncol. 2018 Apr; 25(2): 163–169. Published online 2018 Apr 30. doi:  3747/co.25.4044 PMID: 29719432
  2. Cremin CHoward SLe LKarsan ASchaeffer DFRenouf DSchrader KA. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. Hered Cancer Clin Pract.2018 Mar 7;16:7. doi: 10.1186/s13053-018-0088-y. eCollection 2018. PMID:29541281
  3. Liu K, Lu XJ, Cheng Y, Klieb H, Ng S, McNeil K, Karsan A, Poh C. An actionable test using loss of heterozygosity in identifying high-risk oral premalignant lesions. OralSurg Oral Med Oral Pathol Oral 2017 Dec 18. pii: S2212-4403(17)31208-7. doi: 10.1016/j.oooo.2017.10.019. PMID: 29428696
  4. Zhao EYShen YPleasance EKasaian KLeelakumari SJones MBose PCh’ng CReisle CEirew PCorbett RMungall KLThiessen NMa YSchein JEMungall AJZhao YMoore RADen Brok WWilson SVilla DShenkier TLohrisch CChia SYip SGelmon KLim HRenouf DSun SSchrader KAYoung SBosdet IKarsan A,Laskin JMarra MAJones SJM. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941. PMID 29246904
  5. Enfield K,  Marshall E,  Ng K, Anderson C, Rahmati S,  Lam S,  Macaulay C,  Lockwood W,  Karsan A,  Jurisica I,  Lam Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth. Journal of Thoracic Oncology. November 2017 Volume 12, Issue 11, Supplement 2, Page S1763 DOI:
  6. Tsao M, Zhang T,Cheema P, Laskin J, Karsan A, Barnes T, Liu G, Owen S, Rothenstein J, Burkes R,  Iqbal M, Spatz A, Izevbaye I, Kempen L, Kamel-Reid S, Leighl Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing Journal of Thoracic Oncology, November 2017, Volume 12, Issue 11, Supplement 2, Page S2207 DOI:
  7. Grewal JK, Eirew P, Jones M, Chiu K, Tessier-Cloutier B, Karnezis AN, Karsan A, Mungall A, Zhou C, Yip S, Tinker AV, Laskin J, Marra M, Jones SJM. Detection and Genomic Characterization of a mammary-like adenocarcinoma. Cold Spring Harb Mol Case Stud.2017 Nov 21;3(6). pii: a002170. doi: 10.1101/mcs.a002170. PMID: 28877932
  8. Lai CKNorddahl GLMaetzig TRosten PLohr TSanchez Milde Lvon Krosigk NDocking TRHeuser MKarsan AHumphries RK. Meis2 as a critical player in MN1-induced leukemia. Blood Cancer J.2017 Sep 29;7(9):e613. doi: 10.1038/bcj.2017.86. PMID: 28960191
  9. Yi YTsai SHCheng JCWang EYAnglesio MSCochrane DRFuller MGibb EAWei WHuntsman DGKarsan AHoodless PA. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol Oncol.2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. December 2017. PMID: 29079036
  10. Wong HLYang KCShen YZhao EYLoree JMKennecke HFKalloger SEKarasinska JMLim HJMungall AJFeng XDavies JMSchrader KZhou CKarsan AJones SJLaskin JMarra MASchaeffer DFGorski SMRenouf DJ. Molecular characterisation of metastatic pancreatic neuroendocrine tumours (PNETs) using whole genome and transcriptome sequencing. Cold Spring Harb Mol Case Stud.2017 Nov 1. pii: mcs.a002329. doi: 10.1101/mcs.a002329. PMID:29092957
  11. Chang KTEGoytain ATucker TKarsan ALee CHNielsen TONg TL. Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform. J Mol Diagn.2017 Nov 17. pii: S1525-1578(17)30314-8. doi:10.1016/j.jmoldx.2017.09.007. PMID: 29104083
  12. Hout DRSchweitzer BLLawrence KMorris SWTucker TMazzola RSkelton RMcMahon FHandshoe JLesperance MKarsan ASaltman DL.Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer. Cancers (Basel).2017 Aug 1;9(8). pii: E99. doi: 10.3390/cancers9080099 PMID: 28763012
  13. Lebo MSZakoor KRChun KSpeevak MDWaye JSMcCready EParboosingh JSLamont REFeilotter HBosdet ITucker TYoung SKarsan ACharames GSAgatep RSpriggs ELChisholm CVasli NDaoud HJarinova OTomaszewski RHume STaylor SAkbari MRLerner-Ellis JCanadian Open Genetics Repository Working Group. Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR).Genet Med. 2017 Jul 20. doi: 10.1038/gim.2017.80. PMID:28726806
  14. Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, and Tsao MS. Management of EGFR Mutated NSCLC: Practical Implications from   a Clinical and Pathology Perspective. Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524.  PMID: 28490925
  15. Weymann D, Laskin J, Roscoe R, Schrader I, Chia S, Yip S, Cheung W, Gelmon K, Karsan A, Renouf D, Marra M, Regier D. The cost and cost-trajectory of whole-genome analysis guiding treatment of  patients with advanced cancers. Clin Genet. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. PMID: 28546995
  16. Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch’ng C, Thomas R, Ng T, Yip S, J Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, J Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001628. doi: 10.1101/mcs.a001628. Print 2017 Sep. PMID: 28514723
  17. Goy J, Gillan T, Huang S, Karsan A, Ramadan K, Bruyere H, Toze C, Gerrie A, Hrynchak M and Connors J. Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of  first-line therapy, but long overall survival: results of a population-based cohort in British Columbia,      Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):382-389. pii: S2152-2650(17)30205-7. doi: 10.1016/j.clml.2017.04.001. PMID: 28559149
  18. O’Neill K, Hills M, Gottlieb M, Karsan A and Lansdorp P. Assembling Draft Genomes using contiBAIT. Bioinformatics.2017 Sep 1;33(17):2737-2739. doi: 10.1093/bioinformatics/btx281.PMID: 28475666
  19. Foroushani A, Agrahari R, Docking R, Chang L, Duns G, Hudoba M, Karsan A*, Zare H* (co-senior authors). Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC Med Genomics. 2017 Mar 16;10(1):16. PMID: 28298217
  20. Huang SJ, Lee LJ, Gerrie AS, Gillan TL, Bruyere H, Hrynchak M, Smith AC, Karsan A, Ramadan KM, Jayasundara KS, and Toze CL. Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada. Leuk Res. 2017 Jan 15;55:79-90. PMID: 28157628
  21. Huang S, Gerrie A, Bergin K, Gillan T, Bruyere H, Smoth A, Ramadan K, Karsan A, Dalal C, Toze C, Azue K. Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada. Cancer Genet. 2017 Jan: 210:1-8. PMID: 28212806
  22. Stunnenberg HG; International Human Epigenome Consortium, Hirst M. The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell. 2016 Nov 17;167(5):1145-1149. PMID: 27863232
  23. Busque L, Porwit A, Day R, Olney H, Leber B, Ethier V, Sirhan S, Foltz L, Prchal J, Turner R, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPN): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016 Oct;146(4):408-22. PMID: 27686169
  24. Patenaude A and Karsan, A. A Novel Population of Local Pericyte Precursor Cells in Tumor Stroma that Require Notch Signaling for Differentiation. J Cell Signal. 2016 May. 1:115. doi:10.4172/jcs.1000115. PMID: 26092680
  25. Lund H, Hughesman C, Fakhfakh K, McNeil K, Clemens S, Hocken K, Pettersson R, Karsan A, Foster L, Haynes C. Initial Diagnosis of ALK-Positive Non-Small-Cell Lung Cancer Based on Analysis of ALK Status Utilizing Droplet Digital PCR. Anal Chem. 2016 May 3;88(9):4879-85. PMID: 27043019
  26. Cressman S, Karsan A, Hogge D, McPherson E, Bolbocean C, Regier D, Peacock S. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. Br J Haematol. 2016 Aug;174(4):526-35. PMID: 27098559
  27. Young S, Tucker T, Bosdet I, Karsan A. Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach. Leukemia. 2016 Jul;30(7):1628-9. PMID: 26952806
  28. Parker J, Shen Y, Pleasance E,  Li Y, Schein J, Zhao Y, Moore R, Wegrzyn-Woltosz J, Savage K, Weng A, Gascoyne R, Jones S, Marra M, Laskin J, Karsan A. Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. Cold Spring Harb Mol Case Stud. 2016 March 2. Stud 2:  PMID: 27148583
  29. Lund H, Hughesman C, McNeil K, Clemens S, Hocken K, Pettersson R, Karsan A, Foster L, Haynes C. Initial Diagnosis of Chronic Myelogenous Leukemia Based on Quantification of M-BCR Status Using Droplet Digital PCR. Anal Bioanal Chem. 2016 Feb;408(4):1079-94. PMID: 26631023
  30. Huang S, Gillan T, Gerrie A, Hrynchak M, Karsan A, Ramadan K, Smith A, Toze C, Bruyere H. Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada. Genes Chromosomes Cancer. 2016 Jan;55(1):16-24. PMID:26391112
  31. Bidshahri R, Attali D, Fakhfakh K, McNeil K, Karsan A, Won J, Wolber R, Bryan J, Hughesman C, Haynes C. Quantitative detection and resolution of BRAF V600 status in colorectal cancer using droplet digital PCR and a novel wild-type negative assay. J Mol Diagn. 2016 Mar;18(2):190-204. PMID: 26762843
  32. Laskin J, Jones S, Aparicio S, Chia S, Ch’ng C, Deyell R, Eirew P, Fok A, Gelmon K, Ho C, Huntsman D, Jones M, Kasaian K, Karsan A, Leelakumari S, Li Y, Lim H, Ma Y, Mar C, Martin M, Moore R, Mungall A, Mungall K, Pleasance E, Rassekh S, Renouf D, Shen Y, Schein J, Schrader K, Sun S, Tinker A, Zhao E, Yip S, Marra M. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud. 2015 Oct 27. 1: a000570. PMID: 27148575
  33. Varney M, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, Maciejewski J, Meetei R, Inoue J, Starczynowski D. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J Exp Med. 2015 Oct 19;212(11):1967-85. PMID: 26458771
  34. Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun S, Mah S, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski D, Karsan A, Heuser M, Hogge D, Camargo F, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries R, Kuchenbauer F. MicroRNA-223 dose-levels fine-tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol. 2015 Oct;43(10):858-868.e7. PMID:26163797
  35. Patenaude A, Woerher S, Umlandt P, Wong F, Ibrahim R, Kyle A, Unger S, Fuller M, Parker J, Minchinton A, Eaves C, Karsan A. A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. Microvasc Res. 2015 Sep;101:38-47. PMID: 26092680
  36. Lerner-Ellis J, Wang M, White S, Lebo M, Agatep R, Ainsworth P, Akbari MR, Aronson M, Bader GD, Basran R, Blavier A, Blumenthal A, Buckley K, Campbell J, Campeau PM, Care M, Carson N, Carter R, Charames G, Chitayat D, Chong G, Chouinard E, Chun K, Craddock KJ, Docking R, Eisen A, Faghfoury H, Farrell S, Feilotter H, Fernandez B, Forster-Gibson C, Foulkes W, Hegele R, Holter S, Horsburgh S, Hughes L, Hume S, Jewett F, Karsan A, Khalouei S, Knoll J, Kolomeitz E, Maire G, Marshall C, McCready E, Moorhouse MJ, Morel C, Nelson T, O’Connor B, Ouellette F, Parboosingh J, Ray P, Rehm H, Riddell C, Rosenblatt DS, Ruchon A, Sadikovic B, Semotiuk K, Scherer SW, Shuman C, Silver J, Siminovitch K, Solomon-Izsak L, Speevak M, Stavropoulos J, Stein L, Tannenbaum R, Terespolsky D, Wintle RF, Wong B, Wong N, Waye JS, Woods MO, Wyatt P, Young S. Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations. J Med Genet. 2015 Jul;52(7):438-45. PMID:25904639
  37. McGraw K, Zhang L, Rollison D, Basiorka A, Fulp W, Rawal B, Jerez A, Billingsley D, Lin H, Kurtin S, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz M, Cervera J, Such E, González T, Nevill T, Haferlach T, Smith A, Kulasekararaj A, Mufti G, Karsan A, Maciejewski J, Sokol L, Epling-Burnette P, Wei S, List A. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar 13;5:e291. PMID:25768405
  38. Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Mourad YA, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):341-8. PMID:25656914
  39. O’Neill K, Aghaeepour N, Parker J, Hogge D, Karsan A, Dalal B, Brinkman R. Deep profiling of multitube flow cytometry data. Bioinformatics. 2015 May 15;31(10):1623-31. PMID:25600947
  40. Birol I, Raymond A, Chiu R, Nip K, Jackman S, Kreitzman M, Docking T, Ennis C, Robertson A, Karsan A. Kleat: cleavage site analysis of transcriptomes. Pac Symp Biocomput. 2015, Jan; 20:347-58. PMID:25592595
  41. Kulic I, Robertson G, Chang L, Baker J, Lockwood W, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson M, Chun H, Gilks B, Kempkes B, Thomson T, Hirst M, Minchinton A, Lam W, Jones S, Marra M, Karsan A. Loss of the Notch effector RBPJ promotes tumorigenesis. J Exp Med. 2015 Jan 12; 212(1):37-52. PMID:25512468
  42. Sheffield B, Bosdet I, Ali R, Young S, McNeil B, Wong C, Dastur K, Karsan A, Ionescu D. Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer.  Curr Oncol. 2014 Dec; 21(6):305-8. PMID:25489257
  43. Gerrie A, Huang S, Bruyere H, Chinmay D, Hrynchak M, Karsan A, Ramadan K, Smith A, Tyson C, Toze C, Gillian T. Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization. Cancer Genet. 2014 Jul-Aug; 207(7-8):316-25. PMID:25441686
  44. Lai C, Moon Y, Kuchenbauer F, Starzcynowski D, Argiropoulos B, Yung E, Beer P, Schwarzer A, Sharma A, Park G, Leung M, Lin G, Vollett S, Fung S, Eaves C, Karsan A, Weng A, Humphries R, Heuser M. Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene. PLoS One. 2014 Nov 17; 9(11):e112671. PMID:25401736
  45. Cutz J, Craddock K, Torlakovic E, Brandao G, Carter R, Bigras G, Deschenes J, Izevbaye I, Xu Z, Greer W, Yatabe Y, Ionescu D, Karsan A, Jung S, Fraser R, Blumenkrantz M, Lavoie J, Fortin F, Bojarski A, Cote G, van den Berghe J, Rashid-Kolvear F, Trotter M, Sekhon H, Albadine R, Tran-Thanh D, Gorska I, Knoll J, Xu J, Blencowe B, Iafrate A, Hwang DM,Pintilie M, Gaspo R, Couture C, Tsao M. Canadian Anaplastic Lymphoma Kinase (ALK) study: A model for multi-centre standardization and optimization of novel biomarker tests in lung cancer. Journal of Thoracic Oncology. 2014 Sep;9(9):1255-63. PMID:25122422
  46. Chang A, Garside V, Fournier M, Smrz J, Vrljicak P, Umlandt P, Fuller M, Robertson G, Zhao Y, Tam A, Jones S. Marra M, Hoodless P, Karsan A. A Notch-dependent transcriptional hierarchy promotes mesenchymal transdifferentiation in the cardiac cushion. Dev Dyn. 2014 Jul;243(7):894-905. PMID:24633789
  47. Patenaude A, Fuller M, Chang L, Wong F, Paliouras G, Shaw R, Kyle A, Umlandt P, Baker J, Diaz E, Tong J, Minchinton A, Karsan A. Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.  Cancer Res. 2014 May 1;74(9):2402-11. PMID:24599126
  48. Mariano C, Bosdet I, Karsan A, Ionescu D, Murray N, Laskin J, Zhai Y, Melosky B, Sun S, Ho C. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. 2014 Jan;83(1):73-7. PMID:24192511
  49. Wilson I, Vucic E, Enfield K, Thu K, Zhang Y, Chari R, Lockwood W, Radulovich N, Starczynowski D, Banáth J, Zhang M, Pusic A, Fuller M, Lonergan K, Rowbotham D, Yee J, English J, Buys T, Selamat S, Laird-Offringa I, Liu P, Anderson M, You M, Tsao M, Brown C, Bennewith L, MacAulay C, Karsan A, Gazdar A, Lam S, and Lam W. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. 2014 Sep 4;33(36):4464-73. PMID:24096489
  50. Bosdet I, Docking R, Butterfield Y, Mungall A, Zeng T, Coope R, Yorida E, Chow K, Young S, Hirst M, Birol I, Moore R, Jones S, Holt R, Karsan A. A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations. J Mol Diagn. 2013 Nov; 15(6):796-809. PMID:24094589
  51. El-Sehemy A, Chang A, Azad A, Gupta N, Xu Z, Steed H, Karsan A, Fu YX. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells. Cell Signal. 2013 Dec;25(12):2780-7. PMID:24041655
  52. Swanson L, Robertson G, Mungall K, Butterfield Y, Chiu R, Corbett R, Docking R, Hogge D, Jackman S, Moore R, Mungall A, Nip K, Parker J, Qian J, Raymond A, Sung S, Tam A, Thiessen N, Varhol R, Wang S, Yorukoglu D, Zhao Y, Hoodless P, Sahinalp C, Karsan A, Birol I. Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. BMC Genomics, 2013 Aug 14; 14:550. PMID:23941359
  53. Dauphinee S, Clayton A, Hussainkhel A, Yang C, Park Y, Fuller M, Blonder J, Veenstra T, Karsan A. SASH1 is a scaffold molecule in endothelial TLR4 signaling. J Immunol. 2013 Jul 15;191(2):892-901. PMID:23776175
  54. Chang L, Wong F, Niessen K, Karsan A. Notch activation promotes endothelial survival through a PI3K-Slug axis. Microvasc Res. 2013 Sep;89:80-5. PMID:23743248
  55. Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A, Hoadley K, Triche Jr T, Laird P, Baty J, Fulton L, Fulton R, Heath S, Kalicki-Veizer J, Kandoth C, Klco J, Koboldt D, Kanchi K-L, Kulkarni S, Lamprecht T, Larson D, Lin L, Lu C, McLellan M, McMichael J, Payton J, Schmidt H, Spencer D, Tomasson M, Wallis J, Wartman L, Watson M, Welch J, Wendl M, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun H, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt R, Jones S, Karsan A, Lee D, Li H, Marra M, Mayo M, Moore R, Mungall L, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Sougnez C, Zou L, Leiserson M, Vandin F, Wu H, Appelbaum F, Baylin S, Akbani R, Broom B, Chen K, Motter T, Nguyen K, Weinstein J, Zhang N, Ferguson M, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok J, Mills Shaw K, Sheth M, Sofia H, Yang L, Downing J, Eley G, Alonso S, Ayala B, Baboud J, Backus M, Barletta S, Berton D, Chu A, Girshik S, Jensen M, Kahn A, Kothiyal P, Nicholls M, Pihl T, Pot D, Raman R, Sanbhadti R, Snyder E, Srinivasan D, Walton J, Wan Y, Wang Z, Issa J, Le Beau M, Carroll M, Kantarjian H, Kornblau S, Bootwalla M, Lai P, Shen H, Van Den Berg D, Weisenberger D, Link D, Walter M, Ozenberger B, Mardis E, Westervelt P, Graubert T, DiPersio J, Wilson R. The Genomic and Epigenomic Landscape of Adult de novo Acute Myeloid Leukemia. N Engl J Med. 2013 May 30;368(22):2059-74. PMID:23634996
  56. Chang A, Patenaude A, Lu K, Fuller M, Ly M, Kyle A, Golbidi S, Wang Y, Walley K, Minchinton A, Laher I, Karsan A. Notch-Dependent Regulation of the Ischemic Vasodilatory Response. Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):510-2. PMID:23288167
  57. Venner C, Wegrzyn Woltosz J, Nevill T, Deeg H, Caceres G, Platzbecker U, Scott B, Sokol L, Sung S, List A, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome. 2013 Mar;98(3):409-13. PMID:22929976
  58. Wong N, Fuller M, Sung S, Wong F, Karsan A. Heterogeneity of breast cancer stem cells as evidenced with Notch-dependent and Notch-independent populations. Cancer Med. 2012 Oct; 1(2):105-113. PMID:23342261


  • Senior Research Fellow (Hematology), University of Washington, 1997
  • Residency, University of British Columbia, Canada, 1993
  • Intership, Lions Gate Hospital, Canada, 1987
  • M.D., Queen’s University at Kingston, Canada, 1986
  • B.A. (Life Science), Queen’s University at Kingston, Canada, 1983